Eusol Biotech, established in 2005 in Taipei, Taiwan, focuses on the research and development of recombinant human acid fibroblast growth factor (rhFGF1), a protein with significant potential in various medical applications. The company is actively engaged in the GMP process development of this growth factor, which is currently being explored for its efficacy in treating spinal cord injuries and peripheral nerve injuries, such as carpal tunnel syndrome. The ES135 protein drug, a key product in their pipeline, has undergone extensive clinical trials involving approximately 300 patients across multiple phases, highlighting its promising therapeutic potential.

In addition to ES135, Eusol Biotech is developing several other products, including SM-1, a combination sleeping aid, and two small molecule drugs, EPS221 and EPS222, which target selective serotonin reuptake inhibition and cardiovascular disease, respectively. The company is also preparing to expand its offerings through licensing approved medicines and co-developing new drugs with pharmaceutical partners under the 505(b)(2) regulatory pathway. This strategic approach underscores Eusol Biotech's commitment to advancing innovative therapies and enhancing its research and development capabilities in the biopharmaceutical sector.

Taiwan

Eusol Biotech was founded in March 2005 in Taipei, Taiwan. The company is involved in the R&D and GMP process development of recombinant human acid fibroblast.

Eusol Biotech

Company Details